23 January, 2021
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency and quantity of drinking and heavy drinking with no overt safety concerns.
Genetically Targeted
Designed to reduce craving to effectively curb alcohol intake in those patients with the genetics expected to indicate a likely response to treatment with AD04
BRINGS 20+ YEAR TRACK RECORD OF CLINICAL USE
To date, clinical testing of AD04 has shown it to have a positive safety and tolerability profile with side effects similar to placebo.
Oral daily dosing
Our product candidate is intended to be easy to use since it is administered orally.
AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption
Email Alerts
SIGN UP TODAYLatest Tweets
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion $ADIL
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
bit.ly
Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants $ADIL
Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants
bit.ly
We are pleased to announce Adial has reached the 50% enrollment in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial. $ADIL
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
bit.ly
AD04 Ready to Enter Phase 3 in Targeted Groups
Adial has commenced a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04.
Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.